Research article: Reevaluation of the Bicycle Ergometry in the Diagnosis of Ischemic Heart Disease

Authors' list: Basheer Abdullah Marzoog^{1,*}, Peter Chomakhidze ¹, Philipp Kopylov ¹

¹ World-Class Research Center «Digital Biodesign and Personalized Healthcare», I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991.

*Corresponding author: Basheer Abdullah Marzoog, MD, Ph.D. cardiology student at Sechenov First Moscow State Medical University at the World-Class Research Center "Digital biodesign and personalized healthcare". (marzug@mail.ru, +79969602820). Address: Russia, Moscow, 8-2 Trubetskaya street, 119991. Postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991. ORCID: 0000-0001-5507-2413, Scopus ID: 57486338800

Competing interests: No competing interests regarding the publication.

Abstract

Background: Ischemic heart disease (IHD) and related complications and outcomes remain the most frequently reported cardiovascular events. However, the diagnosis and prevention of ischemic heart disease primary depends on the clinical manifestations and electrocardiography changes.

Objectives: Patients with IHD are victims of the poor diagnostic methods and the prevention strategies.

Aims: To assess the diagnostic accuracy of the used bicycle ergometry in the diagnosis of ischemic heart disease based on the results of the stress computed myocardial perfusion (CTP) imaging with vasodilator test (adenosine triphosphate).

Materials and methods: A single center prospective, and non-randomized study included participations aged ≥ 40 . The study included 38 participants with vs without IHD confirmed by CTP. The participants done bicycle ergometry following Bruce protocol then performed CTP. For statistical analysis used the descriptive statistics, Pearson Correlation test, Student test. The Statistica 12 program used for the statistical test.

Results: The study included 38 participants included 19 (50 %) patients with positive stress induced myocardial perfusion defect on the CTP and 19 (50 %) with negative results. The mean age of the participants 58,77 years (std. div. \pm 9,664). The bicycle ergometry specificity and sensitivity 61.11%, 57.89%, respectively. The diagnostic accuracy of the bicycle ergometry 59.46%.

Conclusions: The bicycle ergometry test characterized by severe limitations in terms of the IHD diagnosis.

Others: Recommended to combine additional diagnostic methods with the bicycle ergometry to improve it is diagnostic accuracy, such as single channel electrocardiography and exhaled breath analysis.

Keywords: Ischemic heart disease, Bicycle Ergometry, Stress Computed Tomography Myocardial Perfusion Imaging, Diagnosis

Introduction

Ischemic heart disease (IHD) is one of the most common pathologies among the cardiovascular disease in terms of the mortality and morbidity ^[1]. This high prevalence of IHD in the community returns to the poor early detection and diagnostic methods of IHD. One of the most frequently used diagnostic method for individuals with clinical signs and symptoms of ischemic heart disease is the physical stress test, including bicycle ergometry ^[2]. The debate about the efficacy of this method is under evaluation since it is first use in clinical practice ^[3, 4]. However, this method is easy to use and safe as well as cost-effective. Therefore, this method is widespread as an elementary diagnostic method for IHD in compare to other expansive and invasive methods such as coronary angiography with Coronary Flow Reserve ^[5].

The current paper revises the specificity and sensitivity of the bicycle ergometry for usage as an elementary tool for IHD diagnosis through performing research on a participant with specific inclusion and exclusion criteria (published on the clinical trial (NCT06181799).

Materials and methods

A non-randomized, single center, mini-invasive, parallel, cross-sectional, diagnostic, observational, case-control prospective cohort study performed at the University Clinical Hospital-1. The data of this study extracted from another clinical trial performed by Marzoog, the full design of the study published on clinicaltrials.gov (NCT06181799) ^[6]. The study approved by the Sechenov University, Russia, from "Ethics Committee Requirement № 19-23 from 26.10.2023".

The study included both males and females, and the age of the participants \geq 40 years. The study participants passed exercise bicycle ergometry (on SCHILLER device; Bruce protocol) test to evaluate the response to physical activity. According to the results metabolic equivalent; Mets-BT (BT), the angina functional class (FC) in participants with positive physical stress test results determined, Where BT/Mets <50/<4 FC-III, BT/Mets 50-100/4-7 FC-II, BT/Mets >100/7 FC-I. During the bicycle ergometry, the participants monitored with 12-lead ECG and manual blood pressure measurement, 1 measured at the end of each 2 minute.

The ergometry procedure discontinued if an increase in blood pressure ≥ 220 mmHg or horizontal or downsloping ST segment on the ECG ≥ 1 mm. Moreover, stop the procedure if the target heart rate (86% of the 220-age) is reached.

To perform the stressed myocardial perfusion computer tomography imaging, all the participants present results of the venous creatinine level, eGFR (estimated glomerular filtration rate) according to the 2021 CKD-EPI Creatinine > 30 ml/min/1,73 m2, according to the recommendation for using this formula by the National kidney foundation and the American Society of Nephrology [7–10].

The participants got catheterization in the basilar vein or the radial vein for injection of contrast and Natrii adenosine triphosphate (10 mg/1ml) to induce pharmacological stress test to the heart by increasing heart rate.

To prepare the Natrii adenosine triphosphate, an Adenosine triphosphate 3 ml dilute in 17 ml of Isotonic Sodium Chloride Solution 0.9%, the injected volume of the diluted drug in milliliters is calculated by body weight. For 1 dose, take 3 ml of adenosine triphosphate (3 ampoules of each 1 ml (10mg)) + 17 ml of isotonic solution of sodium chloride 0.9% in one syringe, 20 ml. For one patient, manually inject intravenously (IV) through the already inserted catheter at a rate of 300 μ g/kg/2 minutes, depending on weight: 60 kg = 12 ml, 70 kg = 14 ml. 80 kg = 16 ml, 100 kg = 20 ml of the full dose.

Computer tomography (Canon with 640 slice, 0,5mm thickness) with contrast (Omnipaque, 350-100ml), inject the contrast, then make rest image for myocardial perfusion, then wait 20 minutes and then inject the Natrii adenosine triphosphate intravenously (10 mg/1ml) according to the body weight to cause pharmacological stress test to the heart during two minutes in to the catheter. Then make the second image of the myocardial perfusion after stress test immediately.

Results

The descriptive statistic of the continuous variables demonstrated in table 1.

Table 1: Descriptive statistics of the presented sample.

	Descriptive Statistics (All in primary data.stw)				
Variable	Valid N	% Valid obs.	Mean	Minimum	Maximum
Age (years)	38	100.0000	58.77	42.05	77.94
Pulse rate (beat per minute)	38	100.0000	72.21	53.00	92.00
SBP (mmHg)	38	100.0000	122.47	100.00	155.00
DBP (mmHg)	38	100.0000	77.84	60.00	100.00
Body weight (Kg)	38	100.0000	75.92	52.50	118.30
Height (cm)	38	100.0000	171.29	148.00	190.00
BMI $((kg/m^2)$	38	100.0000	25.84	18.49	35.00
Goal heart rate (220-age)	38	100.0000	161.23	142.06	177.95
Max HR (beat per minute)	38	100.0000	148.08	108.00	199.00
Reached % on bicycle ergometry	38	100.0000	92.18	64.89	135.25
WT	38	100.0000	119.74	75.00	250.00
METs	38	100.0000	6.59	3.40	11.90
Creatinine (µmol/L)	38	100.0000	85.14	57.00	138.00
eGFR (2021 CKD-EPI Creatinine)	38	100.0000	82.04	45.40	107.00

The number of patients with normal body weight 17 (44.73684 %). overweight 15 (39.47368 %), and obesity first degree 6 (15.78947 %).

The categorical variables are presented as a relative and absolute values in table 2 (A-W)

Table 2: The table represents the categorical variables of the study in absolute and relative values.

2-A

	Frequency tal	ble: Smoking (All in p	rimary data.stw)	
Category	Count	Cumulative	Percent	Cumulative
		Count		Percent
No	33	33	86.84211	86.8421
Yes	5	38	13.15789	100.0000
Missing	0	38	0.00000	100.0000

2-B

	Frequency	Frequency table: Concomitant disease (All in primary data.stw)				
Category	Count	Cumulative	Percent	Cumulative		
		Count		Percent		
No	22	22	57.89474	57.8947		
Yes	13	35	34.21053	92.1053		
Missing	3	38	7.89474	100.0000		

2-C

Category	Frequency table: Atherosclerosis of the coronary artery (All in primary data.stw)					
	Count Cumulative Percent Cumulative					
		Count		Percent		
No	19	19	50.00000	50.0000		
Yes	19	38	50.00000	100.0000		
Missing	0	38	0.00000	100.0000		

2-D

Category	Frequency table: Hemodynamically significant (>60%) (All in primary data.stw)					
	Count Cumulative Percent Cumulative					
		Count		Percent		
No	33	33	86.84211	86.8421		
Yes	5	38	13.15789	100.0000		
Missing	0	38	0.00000	100.0000		

2-E

	Frequency table: Myocardial perfusion defect after stress ATP (A				
Category	primary data.stw)				
	Count	Cumulative	Percent	Cumulative	
		Count		Percent	
No	19	19	50.00000	50.0000	

Category	Frequency table: Myocardial perfusion defect after stress ATP (All in primary data.stw)			
	Count	Cumulative	Percent	Cumulative
		Count		Percent
Yes	19	38	50.00000	100.0000
Missing	0	38	0.00000	100.0000

2-G

Category		Frequency table: Myocardial perfusion defect before Stress ATP (All i primary data.stw)					
outegory .	Count	Count Cumulative Percent Cumulative					
		Count		Percent			
Yes	13	13	34.21053	34.2105			
No	25	38	65.78947	100.0000			
Missing	0	38	0.00000	100.0000			

2-H

Category	Frequency data.stw)	Frequency table: Atherosclerosis in other arteries (Yes/No) (All in primary data.stw)				
	Count	Cumulative Count	Percent	Cumulative Percent		
No	18	18	47.36842	47.3684		
Yes	15	33	39.47368	86.8421		
Missing	5	38	13.15789	100.0000		

2-I

Category	Frequency table: Atherosclerotic vascular (Namely (All in primary data.stw)				
	Count	Cumulative	Percent	Cumulative	
		Count		Percent	
Carotid, Brachiocephalic bifurication	12	12	31.57895	31.5789	
Carotid, Brachiocephalic bifurcation	2	14	5.26316	36.8421	
Carotid	1	15	2.63158	39.4737	
Missing	23	38	60.52632	100.0000	

2-J

Category	Count	Cumulative	Percent	Cumulative
		Count		Percent
No	20	20	52.63158	52.6316
Yes	14	34	36.84211	89.4737
Missing	4	38	10.52632	100.0000

2-K

	Frequency table: Brachiocephalic (All in primary data.stw)				
Category	Count Cumulative Percent Cumulative				
		Count		Percent	
No	22	22	57.89474	57.8947	

	Frequency	Frequency table: Brachiocephalic (All in primary data.stw)			
Category	Count	Cumulative	Percent	Cumulative	
		Count		Percent	
Yes	12	34	31.57895	89.4737	
Missing	4	38	10.52632	100.0000	

2-L

	Frequency	Frequency table: Arterial Hypertension (All in primary data.stw)				
Category	Count	Cumulative	Percent	Cumulative		
		Count		Percent		
Yes	21	21	55.26316	55.2632		
No	17	38	44.73684	100.0000		
Missing	0	38	0.00000	100.0000		

2-M

Frequency table: Stage AH (All in primary data.stw)				
Category	Count	Cumulative	Percent	Cumulative
		Count		Percent
II	14	14	36.84211	36.8421
I	2	16	5.26316	42.1053
III	5	21	13.15789	55.2632
I	1	22	2.63158	57.8947
Missing	16	38	42.10526	100.0000

2-N

	Frequency	Frequency table: Degree AH (All in primary data.stw)				
Category	Count	Cumulative	Percent	Cumulative		
		Count		Percent		
III	5	5	13.15789	13.1579		
II	5	10	13.15789	26.3158		
I	11	21	28.94737	55.2632		
II	1	22	2.63158	57.8947		
Missing	16	38	42.10526	100.0000		

2-O

	Frequency table: Risk of CVD (All in primary data.stw)				
Category	Count	Cumulative	Percent	Cumulative	
		Count		Percent	
Moderate	14	14	36.84211	36.8421	
High	10	24	26.31579	63.1579	
Low	11	35	28.94737	92.1053	
Very high	3	38	7.89474	100.0000	
Missing	0	38	0.00000	100.0000	

2-P

	Frequency table: SCAD (All in primary data.stw)				
Category	Count	Cumulative	Percent	Cumulative	
	Percent				

	Frequency	Frequency table: SCAD (All in primary data.stw)				
Category	Count	Cumulative	Percent	Cumulative		
		Count		Percent		
No	18	18	47.36842	47.3684		
Yes	3	21	7.89474	55.2632		
Missing	17	38	44.73684	100.0000		

2-Q

	Frequency table: Blood pressure reaction type (All in primary						
Category	data.stw)	data.stw)					
	Count	Cumulative	Percent	Cumulative			
		Count		Percent			
Normotonic	28	28	73.68421	73.6842			
Mild hypertonic	2	30	5.26316	78.9474			
Hypertonic	2	32	5.26316	84.2105			
Asthenic	3	35	7.89474	92.1053			
Hypotonic	3	38	7.89474	100.0000			
Missing	0	38	0.00000	100.0000			

2-R

	Frequency table: FC by WT (All in primary data.stw)				
Category	Count	Cumulative	Percent	Cumulative	
		Count		Percent	
FC-II	7	7	18.42105	18.4211	
FC-I	5	12	13.15789	31.5789	
Missing	26	38	68.42105	100.0000	

2-S

-~					
	Frequency table: FC by METs (All in primary data.stw)				
Category	Count	Cumulative	Percent	Cumulative	
		Count		Percent	
FC-II	7	7	18.42105	18.4211	
FC-I	4	11	10.52632	28.9474	
FC-III	1	12	2.63158	31.5789	
Missing	26	38	68.42105	100.0000	

2-T

Category	Frequency table: Reaction type (positive/negative) (All in prin data.stw)					
	Count Cumulative Percent Cumulative					
		Count		Percent		
Positive	12	12	31.57895	31.5789		
Negative	17	29	44.73684	76.3158		
Suspected	9	38	23.68421	100.0000		
Missing	0	38	0.00000	100.0000		

	Frequency table: Reason of discontinuation (All in				
Category	primary data.stw)				
	Count	Cumulative	Percent	Cumulative	
		Count		Percent	
Horizontal ST depression >1mm	6	6	15.78947	15.7895	
Reach goal HR	32	38	84.21053	100.0000	
Missing	0	38	0.00000	100.0000	

2-V

	Frequency table: Tolerance to exertion (All in primary data.stw)						
Category	Count	Cumulative	Percent	Cumulative			
		Count		Percent			
Close to high	4	4	10.52632	10.5263			
Moderate	23	27	60.52632	71.0526			
Very high	6	33	15.78947	86.8421			
High	4	37	10.52632	97.3684			
Low	1	38	2.63158	100.0000			
Missing	0	38	0.00000	100.0000			

2-W

	Frequency table: CKD stage (All in primary data.stw)						
Category	Count	Cumulative	Percent	Cumulative			
		Count		Percent			
I	16	16	42.10526	42.1053			
II	18	34	47.36842	89.4737			
IIIa	4	38	10.52632	100.0000			
Missing	0	38	0.00000	100.0000			

The results of the student test of the sample represented in table 3 (A-M).

Table 3: The results of the student test of the sample represented. Only statistically significant difference represented in the table.

3-A

Variable	T-tests; Grouping: Gender (All in primary data.stw) Group 1: F					
	Group 2: M	Maan	41	16		37-1: 1 NI
	Mean	Mean	t-value	df	p	Valid N
	F	M				F
SBP rest	117.41	126.57	-2.40957	36	0.021210	17
Body weight	67.85	82.44	-3.58890	36	0.000981	17
Height	164.62	176.69	-4.83464	36	0.000025	17
WT	88.24	145.24	-4.82673	36	0.000025	17
METs	5.81	7.22	-2.24874	36	0.030743	17
Creatinine (µmol/L)	76.05	92.50	-3.65241	36	0.000820	17

	T-tests; Grouping: Gender (All in primary data.stw)
Variable	Group 1: F
	Group 2: M

	Valid N	Std.Dev.	Std.Dev.	F-ratio	р
	M	F	M	Variances	Variances
SBP rest	21	12.654	10.782	1.377398	0.492763
Body weight	21	10.219	13.997	1.876169	0.205644
Height	21	8.795	6.600	1.775870	0.223898
WT	21	17.936	45.839	6.531701	0.000392
METs	21	1.206	2.358	3.822979	0.008835
Creatinine (µmol/L)	21	11.782	15.230	1.670764	0.301144

3-B

Variable	T-tests; Grouping: Concomitant disease (All in primary data.stw) Group 1: No Group 2: Yes						
	Mean No	Mean Yes	t-value	df	p	Valid N No	
Height	173.27	165.62	2.52705	33	0.016476	22	
Reached %	88.58	97.49	-2.30415	33	0.027648	22	
WT	130.68	98.08	2.13328	33	0.040428	22	

Variable	T-tests; Grouping: Concomitant disease (All in primary data.stw) Group 1: No Group 2: Yes						
	Valid N Yes	Std.Dev. No	Std.Dev. Yes	F-ratio Variances	p Variances		
Height	13	8.062	9.622	1.424600	0.461098		
Reached %	13	8.428	14.566	2.987445	0.027287		
WT	13	52.288	21.558	5.882893	0.002912		

3-C

Variable	data.stw) Group 1: No	T-tests; Grouping: Atherosclerosis of the coronary artery (All in primary data.stw) Group 1: No Group 2: Yes					
	Mean	Mean	t-value	df	p	Valid N	
	No	Yes				No	
Age	53.13	64.41	-4.39659	36	0.000093	19	
Goal heart rate	166.87	155.59	4.39659	36	0.000093	19	
Creatinine (µmol/L)	79.40	90.89	-2.35327	36	0.024191	19	

Variable	T-tests; Grouping: Atherosclerosis of the coronary artery (All in primary data.stw) Group 1: No Group 2: Yes						
	Valid N	Valid N Std.Dev. Std.Dev. F-ratio					
	Yes	No	Yes	Variances	Variances		
Age	19	6.825	8.850	1.68168	0.279471		
Goal heart rate	19	6.825	8.850	1.68168	0.279471		
Creatinine (µmol/L)	19	12.642	17.114	1.83250	0.208473		

Variable	T-tests; Grouping: Hemodynamically significant (>60%) (All in primary data.stw) Group 1: No Group 2: Yes						
	Mean No	Mean Yes	t-value	df	p	Valid N No	
SBP rest	120.36	136.40	-2.96948	36	0.005282	33	
Max HR	150.79	130.20	2.97336	36	0.005229	33	

Variable	T-tests; Grouping: Hemodynamically significant (>60%) (All in primary data.stw) Group 1: No Group 2: Yes							
	Valid N	Valid N Std.Dev. Std.Dev. F-ratio			p			
	Yes	No	Yes	Variances	Variances			
SBP rest	5	10.911	13.686	1.573274	0.410528			
Max HR	5	13.713	19.215	1.963335	0.247939			

3-E

	T-tests; Grouping: Myocardial perfusion defect before Stress ATP (All							
Variable	in primary da	in primary data.stw)						
	Group 1: Yes							
	Group 2: No	Group 2: No						
	Mean	Mean	t-value	df	р	Valid N		
	Yes	No			-	Yes		
Max HR	139.15	152.72	-2.70213	36	0.010442	13		
Reached %	86.04	95.37	-2.46004	36	0.018825	13		

Variable	in primary d Group 1: Ye	T-tests; Grouping: Myocardial perfusion defect before Stress ATP (All in primary data.stw) Group 1: Yes Group 2: No						
	Valid N	Std.Dev.	Std.Dev.	F-ratio	р			
	No	Yes	No	Variances	Variances			
Max HR	25	14.899	14.573	1.045192	0.886020			
Reached %	25	9.231	11.919	1.667134	0.357847			

3-F

Variable	T-tests; Grouping: Atherosclerosis in other arteries (Yes/No) (All in primary data.stw) Group 1: No Group 2: Yes							
	Mean	Mean	t-value	df	p	Valid N		
	No	Yes				No		
Age	52.16	65.61	-5.29700	31	0.000009	18		
Goal heart rate	167.84	154.39	5.29700	31	0.000009	18		
METs	7.61	5.63	3.03459	31	0.004844	18		

Variable	T-tests; Grouping: Atherosclerosis in other arteries (Yes/No) (All in primary data.stw) Group 1: No Group 2: Yes							
	Valid N Std.Dev.		Std.Dev.	F-ratio	p			
	Yes	No	Yes	Variances	Variances			
Age	15	6.804	7.776	1.30590	0.594317			
Goal heart rate	15	6.804	7.776	1.30590	0.594317			

Variable	T-tests; Grouping: Atherosclerosis in other arteries (Yes/No) (All in primary data.stw) Group 1: No Group 2: Yes							
	Valid N	Std.Dev.	Std.Dev.	F-ratio	p			
	Yes	No	Yes	Variances	Variances			
METs	15	2.452	0.635	14.89954	0.000007			

3-G

Variable	T-tests; Grouping: Atherosclerotic vascular (Namely) (All in primary data.stw) Group 1: Carotid, Brachiocephalic bifurication					
	Group 2: Carotid, Brachiocephalic bifurcation					
	Mean	Mean				
	Carotid, Brachiocephalic	Carotid, Brachiocephalic				
	bifurication	bifurcation				
Max HR	139.33	184.00				
Reached %	90.37	124.61				

Variable	data.stw) Group 1: Caro	T-tests; Grouping: Atherosclerotic vascular (Namely) (All in primary data.stw) Group 1: Carotid, Brachiocephalic bifurication Group 2: Carotid, Brachiocephalic bifurcation					
	t-value	df	p	Valid N Carotid, Brachiocephalic bifurication			
Max HR	-5.07001	12	0.000275	12			
Reached %	-5.00824	12	0.000305	12			

3-H

3 11						
	T-tests; Grouping: Atherosclerotic	vascular (Namely) (All in primary				
Variable	data.stw)					
	Group 1: Carotid, Brachiocephalic bifurication					
	Group 2: Carotid, Brachiocephalic bifurcation					
	Valid N	Std.Dev.				
	Carotid, Brachiocephalic	Carotid, Brachiocephalic				
	bifurcation	bifurication				
Max HR	2	10.210				
Reached %	2	8.173				

	T-tests; Grouping: Atherosclerotic vascular (Namely) (All in						
Variable	primary data.stw)						
	Group 1: Carotid, Brachiocephalic bifurication						
	Group 2: Carotid, Brachiocephalic bifurcation						
	Std.Dev.	F-ratio	р				
	Carotid, Brachiocephalic	Variances	Variances				
	bifurcation						
Max HR	21.2132	4.317	0.123886				
Reached %	15.0526	3.392	0.185215				

3-I

0.2								
	T-tests; Grou	T-tests; Grouping: Carotid (All in primary data.stw)						
Variable	Group 1: No	Group 1: No						
	Group 2: Yes	Group 2: Yes						
	Mean	Mean	t-value	df	р	Valid N		
	No	Yes			_	No		
Age	53.33	66.08	-4.77434	32	0.000038	20		

Variable	T-tests; Grouping: Carotid (All in primary data.stw) Group 1: No Group 2: Yes						
	Mean No	Mean Yes	t-value	df	p	Valid N No	
Goal heart rate	166.67	153.92	4.77434	32	0.000038	20	
METs	7.35	5.56	2.60444	32	0.013842	20	

Variable	· · · · · · · · · · · · · · · · · · ·	T-tests; Grouping: Carotid (All in primary data.stw) Group 1: No						
	Group 2: Ye	Group 2: Yes						
	Valid N	Valid N Std.Dev. Std.Dev. F-ratio p						
	Yes	Yes No Yes Variances						
Age	14	7.532	7.845	1.08495	0.849210			
Goal heart rate	14	7.532	7.845	1.08495	0.849210			
METs	14	2.508	0.597	17.65041	0.000005			

3-J

Variable	Group 1: No	T-tests; Grouping: Brachiocephalic (All in primary data.stw) Group 1: No Group 2: Yes						
	Mean No	Mean Yes	t-value	df	p	Valid N No		
Age	54.18	66.65	-4.38832	32	0.000116	22		
Goal heart rate	165.82	153.35	4.38832	32	0.000116	22		
METs	7.18	5.56	2.24411	32	0.031872	22		

Variable	Group 1: No	T-tests; Grouping: Brachiocephalic (All in primary data.stw) Group 1: No Group 2: Yes			
	Valid N Yes	Std.Dev. No	Std.Dev. Yes	F-ratio Variances	p Variances
Age	12	8.165	7.432	1.20683	0.769942
Goal heart rate	12	8.165	7.432	1.20683	0.769942
METs	12	2.452	0.587	17.45301	0.000023

3-K

Variable	T-tests; Grouping: Arterial Hypertension (All in primary data.stw) Group 1: Yes Group 2: No					
	Mean	Mean Mean t-value df p Valid N				
	Yes	No			1	Yes
Age	62.13	54.62	2.55288	36	0.015067	21
SBP rest	126.00	118.12	2.03149	36	0.049637	21
Goal heart rate	157.87	165.38	-2.55288	36	0.015067	21
METs	5.90 7.44 -2.45597 36 0.019008 21					
eGFR (2021 CKD-EPI Creatinine)	77.32	87.88	-2.16746	36	0.036892	21

Variable	T-tests; Grouping: Arterial Hypertension (All in primary data.stw) Group 1: Yes Group 2: No				
	Valid N	Std.Dev.	Std.Dev.	F-ratio	p
	No	Yes	No	Variances	Variances
Age	17	8.924	9.128	1.04632	0.910887
SBP rest	17	12.235	11.450	1.14179	0.797035
Goal heart rate	17	8.924	9.128	1.04632	0.910887
METs	17	1.407	2.395	2.89929	0.026188

X7 : 11	T-tests; Grouping: Arterial Hypertension (All in primary data.stw)				
Variable	Group 1: Ye				
	Group 2: No)			
	Valid N	Std.Dev.	Std.Dev.	F-ratio	p
	No	Yes	No	Variances	Variances
eGFR (2021 CKD-EPI Creatinine)	17	15.615	14.046	1.23599	0.674001

3-L

	T-tests; Grou	ping: Reaction	type (positiv	/e/nega	ative) (All in p	orimary
Variable	data.stw)					
	Group 1: Positive					
	Group 2: Neg	gative				
	Mean	Mean	t-value	df	р	Valid N
	Positive	Negative				Positive
WT	106.25	144.12	-2.18459	27	0.037776	12

	T-tests; Group	ping: Reaction	type (positive	e/negative) (All	in primary
Variable	data.stw)				
	Group 1: Posi	tive			
	Group 2: Neg	ative			
	Valid N	Std.Dev.	Std.Dev.	F-ratio	р
	Negative	Positive	Negative	Variances	Variances
WT	17	37.119	51.181	1.901152	0.283098

3-M

Variable	T-tests; Grouping: Reason of discontinuation (All in primary data.stw) Group 1: Horizontal ST depression >1mm Group 2: Reach goal HR			
	Mean Horizontal ST depression	Mean Reach goal HR	t-value	df
	>1mm			
Creatinine (µmol/L)	98.62	82.62	2.39629	36

Variable	T-tests; Grouping: Reason of discontinuation (All in primary data.stw) Group 1: Horizontal ST depression >1 mm Group 2: Reach goal HR		
	p	Valid N Horizontal ST depression >1 mm	Valid N Reach goal HR
		Horizontai 31 depression >111111	Reach goal fix
Creatinine (µmol/L)	0.021881	6	32

Variable	T-tests; Grouping: Reason of discontinuation (All in primary data.stw) Group 1: Horizontal ST depression >1mm Group 2: Reach goal HR		
	Std.Dev. Horizontal ST depression	Std.Dev. Reach goal HR	F-ratio Variances
	>1mm		
Creatinine (µmol/L)	23.934	13.007	3.385970

Variable	T-tests; Grouping: Reason of discontinuation (All in
	primary data.stw) Group 1: Horizontal ST
	depression >1 mm
	Group 2: Reach goal HR

	p Variances
Creatinine (µmol/L)	0.029651

Interestingly, the sensitivity and specificity of the bicycle ergometry showed a very low level and not sufficient for confirming the diagnosis of ischemic heart disease. (*Table 4*)

Table 4: The specificity and sensitivity of the bicycle ergometry. (*) These values are dependent on disease prevalence.

Statistic	Value	95% CI
Sensitivity	57.89%	33.50% to 79.75%
Specificity	61.11%	35.75% to 82.70%
Positive Likelihood Ratio	1.49	0.74 to 2.98
Negative Likelihood Ratio	0.69	0.36 to 1.31
Disease prevalence (*)	51.35%	34.40% to 68.08%
Positive Predictive Value (*)	61.11%	43.96% to 75.89%
Negative Predictive Value (*)	57.89%	41.95% to 72.35%
Accuracy (*)	59.46%	42.10% to 75.25%

All the correlation results between the continuous variables presented in supplementary material. (Supplementary file 1)

Dissuasion

Interestingly, on the CTP test, 19 (50 %) participants with coronary artery atherosclerosis, 5 (26 %) of them with significant atherosclerosis (stenosis >60 %). Furthermore, out of the 19 patients with significant atherosclerosis of the coronary artery, 11 (57 %) had myocardial perfusion defect after stress test with ATP.

Out of the 11 patients with positive myocardial perfusion defect after the stress test, 4 (36 %) participants with positive bicycle ergometry test.

More interesting findings, in the whole sample there is 19 (50 %) participants with positive myocardial perfusion defect, and only 5 (26 %) of them with significant coronary artery stenosis. Out of the 19 positive myocardial perfusion defect, 11 (57 %) with positive/suspected results on the bicycle ergometry.

2 (5.26 %) participants out of the 38 with positive results on the bicycle ergometry with heart rate < 85 % of the required goal heart rate (220- age). In other participants with positive (11)/suspected (8) results on the bicycle ergometry with heart rate > 85 % of the required heart rate goal.

In the whole sample there is 12 (31.58 %) positive, 9 (23.68 %) suspected, and 17 (44.47 %) negative on the bicycle ergometry. However, on the CTP, out of the 12 positive bicycle ergometry, only 5 (41.67 %) with positive myocardial perfusion defect after stress test with

ATP. Moreover, out of the 9 suspected participants, 6 (66.67 %) had positive myocardial perfusion defect after stress test with ATP.

The presented results showed that bicycle ergometry suffers from severe limitations in terms of specificity and sensitivity in the diagnosis of IHD. Additional methods are required to improve the diagnostic accuracy of the bicycle ergometry such as the exhaled breath analysis and single channel electrocardiography [11].

Conclusions

On the light of the presented results, the diagnosis of IHD using bicycle ergometry independently is ultra extremely not sufficient and further investigations required to improve the diagnostic accuracy of the bicycle ergometry. As well as to innovate novel methods for early detection of IHD through the application of the current advances in technologies such as the use of artificial intelligence (machine learning models) in the interpretation of the electrocardiography monitoring for patient at home bases using their watches or phones ^[6, 12]. Additionally, supplementary methods can be combined with the bicycle ergometry to enhance it is diagnostic accuracy.

List of abbreviations

IHD; Ischemic heart disease, CTP; stress computed tomography myocardial perfusion imaging

Decelerations

- 1. Ethics approval and consent to participate: The study approved by the Sechenov University, Russia, from "Ethics Committee Requirement № 19-23 from 26.10.2023".
- 2. The study is under consideration by the clinicaltrails.gov for registration.
- 3. Consent for publication: Written informed consent was obtained from the participants for publication of study results and any accompanying images.
- 4. Availability of data and materials: applicable on reasonable request.
- 5. Competing interests: The authors declare that they have no competing interests regarding publication.
- 6. Funding's: The work of Philipp Kopylov and Peter Chomakhidze was financed by the government assignment 1023022600020-6 «Application of mass spectrometry and exhaled air emission spectrometry for cardiovascular risk stratification».
- 7. Authors' contributions: **Basheer Abdullah Marzoog**, is the writer, researcher, collected and analyzed data, and revised the manuscript, **Peter Chomakhidze and Philipp Kopylov** revised the manuscript. All authors have read and approved the manuscript.
- 8. Acknowledgments: not applicable

- Authors' information: Basheer Abdullah Marzoog, World-Class Research Center «Digital Biodesign and Personalized Healthcare», I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991. (marzug@mail.ru, +79969602820). ORCID: 0000-0001-5507-2413. Scopus ID: 57486338800. Peter Chomakhidze, World-Class Research Center «Digital Biodesign and Personalized Healthcare», I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991. ORCID: 0000-0003-1485-6072. Email: m.ba.m@bk.ru. Philipp Kopylov, World-Class Research Center «Digital Biodesign and Personalized Healthcare», I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991. ORCID: 0000-0002-4535-8685. Email: kopylovf_yu@staff.sechenov.ru.
- 10. The paper has not been submitted elsewhere

References

- [1] Tsao, C. W.; Aday, A. W.; Almarzooq, Z. I.; Anderson, C. A. M.; Arora, P.; Avery, C. L.; Baker-Smith, C. M.; Beaton, A. Z.; Boehme, A. K.; Buxton, A. E.; et al. Heart Disease and Stroke Statistics 2023 Update: A Report from the American Heart Association. *Circulation*, 2023, 147 (8), E93–E621. https://doi.org/10.1161/CIR.0000000000001123.
- Yeates, K.; Lohfeld, L.; Sleeth, J.; Morales, F.; Rajkotia, Y.; Ogedegbe, O. A Global Perspective on Cardiovascular Disease in Vulnerable Populations. *Can. J. Cardiol.*,
 2015, 31 (9), 1081–1093. https://doi.org/10.1016/j.cjca.2015.06.035.
- [3] Ofori, E. K.; Frimpong, E.; Ademiluyi, A.; Olawale, O. A. Ergometer Cycling Improves the Ambulatory Function and Cardiovascular Fitness of Stroke Patients—a Randomized Controlled Trial. *J. Phys. Ther. Sci.*, **2019**, *31* (3), 211–216. https://doi.org/10.1589/jpts.28.211.
- [4] Myers, J.; Arena, R.; Franklin, B.; Pina, I.; Kraus, W. E.; McInnis, K.; Balady, G. J. Recommendations for Clinical Exercise Laboratories. *Circulation*, 2009, 119 (24), 3144–3161. https://doi.org/10.1161/CIRCULATIONAHA.109.192520.
- [5] van der Wall, E. E. Alternative Stress Methods in the Evaluation of Coronary Artery Disease. In *Nuclear Cardiology and Cardiac Magnetic Resonance*; Springer Netherlands: Dordrecht, 1992; pp 199–214. https://doi.org/10.1007/978-94-011-2826-

1_11.

- [6] Marzoog, B. A.; Chomakhidze, P.; Kopylov, P. The Biomarkers of Exhaled Breath & Single Channel Electrocardiography in the Diagnosis of Ischemic Heart Disease. *New Emirates Med. J.*, **2024**.
- [7] Cockcroft, D. W.; Gault, M. H. Prediction of Creatinine Clearance from Serum Creatinine. *Nephron*, **1976**, *16* (1), 31–41. https://doi.org/10.1159/000180580.
- [8] Winter, M. A.; Guhr, K. N.; Berg, G. M. Impact of Various Body Weights and Serum Creatinine Concentrations on the Bias and Accuracy of the Cockcroft-Gault Equation. *Pharmacotherapy*, **2012**, *32* (7), 604–612. https://doi.org/10.1002/j.1875-9114.2012.01098.x.
- [9] Brown, D. L.; Masselink, A. J.; Lalla, C. D. Functional Range of Creatinine Clearance for Renal Drug Dosing: A Practical Solution to the Controversy of Which Weight to Use in the Cockcroft-Gault Equation. *Ann. Pharmacother.*, **2013**, *47* (7–8), 1039–1044. https://doi.org/10.1345/aph.1S176.
- [10] Delgado, C.; Baweja, M.; Crews, D. C.; Eneanya, N. D.; Gadegbeku, C. A.; Inker, L. A.; Mendu, M. L.; Miller, W. G.; Moxey-Mims, M. M.; Roberts, G. V.; et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. *Am. J. Kidney Dis.*, 2022, 79 (2), 268-288.e1. https://doi.org/10.1053/j.ajkd.2021.08.003.
- [11] Marzoog, B. A. Breathomics Detect the Cardiovascular Disease: Delusion or Dilution of the Metabolomic Signature. *Curr. Cardiol. Rev.*, 2024, 20. https://doi.org/10.2174/011573403X283768240124065853.
- [12] Marzoog, B. A.; Averina, D. Nicotinamide Mononucleotide in the Context of Myocardiocyte Longevity. *Curr. Aging Sci.*, 2023, 17. https://doi.org/10.2174/0118746098266041231212105020.